Physician profile
Steven Otto
NPI 1154364289
$2,527.32
in general payments reported to CMS, 2019-2025
36 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $496 · 2021: $385 · 2022: $611 · 2023: $321 · 2024: $155 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $452.85 | 2019-2022 | |
| Genzyme Corporation | $268.58 | 2019-2024 | |
| Abbvie INC. | $250.17 | 2021-2022 | |
| Pfizer INC. | $239.80 | 2019-2025 | |
| Emd Serono, INC. | $164.48 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $118.98 | 2019-2023 | Nuplazid |
| Biogen, INC. | $91.71 | 2022-2024 | Tysabri, Vumerity, Spinraza |
| Ucb, INC. | $90.67 | 2019-2024 | Briviact |
| Allergan, INC. | $68.83 | 2019-2020 | |
| Livanova USA, INC. | $65.67 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $59.38 | 2019-2020 | |
| Eisai INC. | $52.78 | 2020-2022 | |
| Horizon Therapeutics Plc | $48.93 | 2022-2023 | Uplizna |
| Harmony Biosciences LLC | $43.13 | 2020 | |
| Alnylam Pharmaceuticals INC. | $42.59 | 2019-2023 | Onpattro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $41.85 | 2020-2023 | Ongentys, Ingrezza |
| Acorda Therapeutics, INC | $37.74 | 2019-2023 | Inbrija |
| Abbott Laboratories | $35.02 | 2024-2025 | Infinity |
| Vanda Pharmaceuticals INC. | $34.03 | 2025 | Ponvory |
| Kyowa Kirin, INC. | $30.56 | 2020-2024 | Nourianz |
| Axsome Therapeutics, INC. | $29.08 | 2023 | Sunosi |
| Biohaven Pharmaceutical Holding Company Ltd. | $26.89 | 2022 | |
| Medtronic Vascular, INC. | $25.34 | 2020 | |
| Amylyx Pharmaceuticals, INC. | $22.86 | 2023 | Relyvrio |
| Sk Life Science, INC. | $19.66 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.96 | 2023 | |
| Xeris Pharmaceuticals, INC. | $18.69 | 2023 | Gvoke Hypopen |
| Merz North America, INC. | $17.09 | 2020 | |
| Mallinckrodt Hospital Products INC. | $17.01 | 2022 | |
| Genentech USA, INC. | $15.22 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $15.01 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.42 | 2019 | |
| Amicus Therapeutics, INC. | $12.55 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Strongbridge US INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Otto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.